AbbVie (NYSE:ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.

AbbVie will present 24 abstracts at AAD, including one late-breaking presentation, with key data reinforcing the company's leadership in advancing standards of care across immune-mediated skin diseases. This robust clinical evidence, spanning a wide range of dermatologic diseases, demonstrates durable and sustained treatment responses, long-term safety and improvements in quality of life, in addition to real-world evidence that reinforce disease control.

"Through our data at AAD, AbbVie reinforces the importance of sustained efficacy and safety to re-shape standards of care and ultimately inform future treatment paradigms that can be transformative for people living with immune-mediated skin diseases," said Andrew Anisfeld, Ph.D., vice president, global medical affairs, immunology, AbbVie. "Our robust evidence across multiple clinical trials and real-world data sources for risankizumab and upadacitinib reaffirm AbbVie's dedication to supporting improved patient outcomes."

Long-term Outcomes in Psoriatic Arthritis and Atopic Dermatitis

  • Maintenance of radiographic nonprogression outcomes in psoriatic arthritis: An analysis reviewing the long-term (five-year) efficacy and radiographic outcomes of risankizumab from the KEEPsAKE-1 Phase 3 trial showed 88% of patients had no radiographic progression (as defined by change in modified Total Sharp Score < 0) through week 244.



     
  • Long-term safety outcomes in atopic dermatitis across age groups: Review of Measure Up 1, Measure Up 2 and AD Up Phase 3 studies across adolescents and adults with moderate-to-serve atopic dermatitis evaluated the safety profile of upadacitinib with exposure of up to six years stratified by age. Across the integrated analysis, 2,683 patients received upadacitinib, representing more than 9,000 patient-years of exposure. Rates of adverse events of special interest (AESIs) were consistent across age groups <65 years old, with higher rates for some AESIs in older adults (≥65 years). Additionally, there were no major cardiovascular adverse events (MACE) reported among adolescents and younger adults (12-49 years).

Quality of Life Impact in Atopic Dermatitis and Psoriasis

  • Real-world evidence evaluating minimal disease activity in atopic dermatitis: New analyses from the AD-VISE real-world study demonstrated treatment outcomes among adults and adolescents with atopic dermatitis receiving upadacitinib in routine clinical practice. In these data, Dermatology Life Quality Index (DLQI) scores of 0 or 1 were achieved by a higher proportion of patients meeting minimal disease activity (72.3%) than those meeting moderate treatment targets (21.7%) or neither treatment target (9.9%).



    Additionally, in evaluating outcomes across body regions, more than half of patients achieved EASI-90 in the head and neck region after six months of upadacitinib treatment, with consistent responses regardless of prior biologic exposure.



     
  • High treatment targets associated with quality of life improvement in psoriasis: A subgroup analysis of 16-week results from the IMMpactful trial evaluating treatment outcomes among biologic-naïve patients with moderate plaque psoriasis receiving risankizumab (RZB) compared with deucravacitinib (DEU) will be presented. Results demonstrated that patients with higher levels of skin clearance (PASI 90 [RZB 57.3% vs DEU 22.9%] and PASI 100 [RZB 27.5% vs DEU 6.5%]), had greater resolution of psoriasis symptoms and quality of life (Psoriasis Symptom Scale 0/1 [RZB 58.0% vs DEU 26.3%] and DLQI 0/1 [RZB 64.1% vs DEU 30.5%]). Findings from the 52-week data set will be presented at a future medical congress this year.



     
  • Quality of life improvement for patients with high impact areas of psoriasis: Genital and scalp psoriasis is associated with increased patient burden and impact on quality of life that can lead to anxiety, depression and social avoidance for some patients.1 The Phase 4 UnlIMMited trial evaluates the efficacy and safety of risankizumab in adult patients with moderate-to-severe genital (Study-G) or scalp (Study-S) psoriasis.2 Results from an analysis of quality of life improvements for patients treated with risankizumab at 16 weeks (assessed by DLQI) showed that 72% to 88.9% achieved individual DLQI 0/1 in Study-G and 83.3% to 100% achieved individual DLQI 0/1 in Study-S.



    Earlier this month, the Food and Drug Administration (FDA) approved the supplemental biologics license application to update the U.S. Prescribing Information for risankizumab-rzaa (SKYRIZI®) with key efficacy and safety results for genital and scalp psoriasis from Study-G and Study-S of the UnlIMMited program.